Teen Cancer America partners with hospitals throughout the United States to develop specialized facilities and services for teens and young adults with cancer. We build teen friendly environments, develop standards for age-targeted care, improve collaboration between pediatric and adult specialists, and support dedicated research to improve outcomes and survival rates.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.